Arca biopharma announces completion of enrollment in phase 2b aspen-covid-19 clinical trial evaluating rnapc2 as a potential treatment for patients hospitalized with covid-19

Westminster, colo., dec. 02, 2021 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in aspen-covid-19, the phase 2b clinical trial evaluating rnapc2 as a potential treatment for patients hospitalized with covid-19.   160 patients were enrolled at clinical investigative sites in the united states, argentina and brazil. the company anticipates reporting topline data from the clinical trial in the first quarter of 2022.
ABIO Ratings Summary
ABIO Quant Ranking